Recruiting
Phase 3

Selected Vegetable & Herb Mix

Sponsor:

Sun Farm Corporation

Code:

NCT00246727

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Selected Vegetable and Herb Mix

Study Details

Brief summary:

The primary objective of these two studies is to test the hypothesis that the daily ingestion of a dietary supplement, Selected Vegetables and Herbs Mix (SV), which consists of non-toxic botanicals containing known anti-cancer and/or immune enhancing components, may prolong the survival time of stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Either SV or placebo will be added to their daily diet in a double-blind randomized fashion, so that there will be 2 chances out of 3 of receiving SV and 1 chance out of 3 of receiving placebo.

  • Study 1: For newly diagnosed patients who will be receiving or have received less than 4 weeks of, a standard chemotherapy regimen.
  • Study 2: For those who have stopped or refuse standard chemotherapy but will receive best supportive care.

Conditions

Non-small Cell Lung Cancer

Study ID

NCT00246727

Start date

Dec, 2005

Status verified date

Oct, 2011

Primary completion date

Dec, 2014

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Pathological and radiographic documented stage IIIB/IV NSCLC (squamous, adenocarcinoma, bronchioloalveolar, large cell, undifferentiated or not otherwise specified non-small cell carcinoma) diagnosed less than two months prior to randomization. Patients must have ECOG performance status of 0-1 and life expectancy >3 months.
  • Patients must never have been diagnosed with any malignancy other than the current NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the cervix.
  • Patients must be >18 years of age.
  • Patients must demonstrate the ability and willingness to eat solid food and SV/placebo.
  • Patients must demonstrate the ability and willingness to give informed consent.
  • Patients must demonstrate the ability and willingness to follow the study requirements.

Exclusion Criteria:

  • Laboratory criteria for exclusion within 14 days prior to randomization.

  • Liver function: bilirubin > 1.5x upper limit of normal (ULN) and SGOT (AST) > 2.5x ULN.
  • Renal function: Serum creatinine >1.5x ULN
  • Bone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3.
  • Hemoglobin <9 gm/dl for males; < 8.5 gm/dl for females.
  • Unexplained temperature > 38.5° C for any 7 consecutive days or chronic diarrhea defined as > 3 stools/day persisting for 15 consecutive days, within the 30 days prior to randomization.
  • Prior chemotherapy within 5 years.
  • Prior radiation to the area of measurable or active tumor.
  • Significant cardiac disease (i.e. uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous year) or serious cardiac arrhythmia requiring medication.
  • Evidence of clinically significant neuropathy (> Grade 1) by physical exam.
  • Patients must not be pregnant or breast-feeding. Female patients of child-bearing potential must have a negative pregnancy test performed within 72 hours prior to randomization. Women of child-bearing potential must agree not to become pregnant while participating in the study.
  • Active acute infection, except for Herpes viruses (cytomegalovirus \[CMV\], Epstein Barr virus \[EBV\], herpes zoster virus \[HZV\], herpes simplex virus 1 \[HSV 1\]).
  • A serious underlying medical condition other than NSCLC such that life expectancy is less than 2 years.
  • Psychiatric illness that may affect the patient's compliance with the treatment.
  • Current use of illicit drugs, glucocorticoids other than those necessary for concurrent radiotherapy, adrenal failure or septic shock, or other immune-suppressing or immune-modulating drugs. Glucocorticoids for anti-emetic prophylaxis and therapy should only be used as a last resort.
  • A known allergy to one or more components of SV, namely soy beans, mushrooms, mung beans, red dates, scallion, garlic, lentil beans, leek, hawthorn fruit, onions, ginseng, angelica root, Chinese licorice, dandelion root, Senegal root, ginger, olives, sesame seed and parsley.

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Study 1: Chemotherapy plus SV or Placebo

For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.

placebo comparator: Study 2: SV vs Placebo without chemotherapy

For those who have stopped or refuse standard chemotherapy but will receive best supportive care.

Interventions

Selected Vegetable and Herb Mix

The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.

Primary outcome measure

  • Survival Time [ Time Frame: Median Survival Time (MST) ]

Central Contacts and Locations

Central contacts

Henry Sacks, MD, Ph.D

212-241-7856henry.sacks@mssm.edu

Locations

Mount Sinai School of Medicine

Recruiting

New York, New York, United States, 10029

Contacts

Henry S Sacks, MD, Ph.D

212-241-7856henry.sacks@mssm.edu

Principal Investigator:

Henry S Sacks, MD, Ph.D

More Information

Sponsor

Sun Farm Corporation

Last update posted

Oct 31, 2011

Last verified

Oct, 2011

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Sun Farm Corporation on 2011-10-31.